Prime Peptides Review
primepeptides.co
Last verified
Peptide Source Tracker is owned and operated by Curo, a research-peptide vendor that appears in these rankings. It is not affiliated with Prime Peptides. Every vendor, including Curo, is scored by the same published methodology.
Research note: Information on this page is compiled from publicly available sources using human and AI-assisted research. See the methodology, each claim's listed source, and the correction policy.
Prime Peptides is operating; it has unconfirmed testing and documentation inputs, and has unconfirmed payment methods. The FDA sent Prime Peptides a warning letter in December 2024 alleging unapproved-new-drug claims involving semaglutide and retatrutide. A warning letter is an allegation of violations, not a finding of guilt.
Published rubric
Scorecard
Documented history
Record
FDA warning letter alleging unapproved-new-drug claims involving semaglutide and retatrutide
FDA Warning Letter 695156 alleged that Prime Vitality, Inc. dba Prime Peptides marketed semaglutide and retatrutide as unapproved new drugs for human use despite research-use-only labeling.
Sources
- agency-warning
Facts
| Domain | primepeptides.co |
| Status | Active — FDA warning letter |
| Last verified | |
| Testing | reported by Finnrick and Peptide Examiner, unverified: Janoshik verification records and Freedom Diagnostics testing |
| Payments | Payment methods unconfirmed |
Related reviews
Is this your company? Dispute or update this record.